Class: Type (195)
Differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or exendin-4 and uses thereof
Patent Number: 7056734This patent is useful for entities seeking to treat diabetes or other pancreatic abnormalities. The patent has very broad claims, all centered around the ability of GLP and Exendin-4 to induce differentiation of cells into insulin produce or amylase producing cells. The patent has 8 independent claims. The first four claims are directed towards use of
Progenitor cells, methods and uses related thereto
Patent Number: 6946293This patent teachs ways of expanding a certain type of pancreatic progenitor cell through the steps of first extracting pancreatic or ductal cells; second, treating the cells with a preparation comprising epidermal growth factor, a cAMP elevating agent, and a steroid or corticosteroid; and , third harvesting a non-adherent population. The first and second independent claims essentially...
Method for generating immune-compatible cells and tissues using nuclear transfer techniques
Patent Number: 6808704This patent teaches methods of generating stem cells using cloning that match the potential recipient according to HLA phenotype. This patent could be very useful since in essence it describes a method of making stem cells that will not be rejected by the immune system.
Mechanically elongated neuronal cells and methods for producing and using these cells
Patent Number: 6365153This patent teaches ways of using physical means to stretch out neuronal cells. These neurons can then be inserted into an animal or human with a nervous system injury. This patent is useful for stem cells since the neurons could be generated from progenitors in vitro, then mechanically modified, then placed into the nervous system of the patient.
Mesenchymal precursor cell
Patent Number: 7,122,178This patent covers a progenitor cell that gives rise to mesenchymal stem cells. The population appears to be highly expressing the marker STRO-1, capable of differentiating into fibroblasts, and have at least one of the following markers: THY-1, VCAM-1, STRO-2, and
Mammalian myeloid progenitor cell subsets
Patent Number: 7,300,760This patent covers a method of extracting or substantially purifying for cells having myeloid stem cell potential. The method covers the selection of cells that are Thy-1 negative, interleukin-7 negative, and lineage negative. By lineage negative the claim means the cells not expressing CD2; CD3; CD4;
Mammalian myeloid progenitor cell subsets
Patent Number: 6761883This is a composition of matter patent on stem cells of the hematopoietic lineage that differentiate specifically into myeloid cells under the appropriate culture and/or in vivo conditions. These stem cells may be used as a "boost" for patients in which the myeloid compartment is not repopulating after bone marrow transplant, or chemotherapy, or radiation therapy.
Mammalian myeloid progenitor cell subsets
Patent Number: 6465247This patent covers a type of stem cell that has differentiated and is committed to the myeloid lineage. This stem cell is useful for inducing a rapid production of myeloid cells such as granulocytes and monocytes, which are protective against bacteria. The cells covered in the patent display the phenotype of c-kit positive, negative for IL-7 receptor (most likely since IL-7 is...
Ependymal neural stem cells and method for their isolation
Patent Number: 7,320,872Glia are the non-neuronal cells of the central nervous system. There are several types of glia. For example, microglia are generally hematopoietically derived cells similar to macrophages that are capable of phagocytosis and clearing local debris. Astrocytes are responsible for physically connecting the neurons to the vasculature feeding them. Astrocytes also regulate the ionic environment...
Multiponent adult stem cells and methods for isolation
Patent Number: 7015037This patent describes a bone marrow stem cell population that is multipotent and capable of differentiating into various lineages besides hematopoietic ones. Specifically, the patent has 5 independent claims, all covering a stem cell isolated from bone marrow. The first covers a CD49c and CD90 postive cell that doubles around every 36...